ENVALITH
株式会社カネカ logo

KANEKA CORPORATION

4118・Prime Market・Chemicals

Official website
株式会社カネカ logo
KANEKA CORPORATION4118

Business

Kaneka Corporation, established in 1949 and listed on the Tokyo Stock Exchange Prime Market, is a comprehensive chemical manufacturer with the brand slogan "A Company that Fulfills Wishes through Chemistry." Its business is organized into four segments: the Material Solutions Unit (materials for social infrastructure and mobility), the Quality of Life Solutions Unit (materials for energy conservation and the information society), the Health Care Solutions Unit (medical devices and pharmaceuticals), and the Nutrition Solutions Unit (functional food materials and foods). The company boasts net sales of ¥811,638 million (FY2026, ending March 2026) and is a global enterprise with an extensive network of group companies both domestically and overseas. Centered on the three fields of environment/energy, food, and health, it provides solutions to societal challenges through an R&D-driven business model.

Business Model

Kaneka develops high-value-added materials and products based on its proprietary chemistry and biotechnology, and sells them to a diverse range of industrial and consumer customers. Its base businesses (Vinyls and Chlor-Alkali, foamed resins, etc.) generate stable cash flow, which is reinvested in R&D and capital expenditure for advanced businesses (Medical, polyimide film, biodegradable biopolymers, etc.), forming a circular structure. R&D expenses amounted to ¥39,891 million and capital expenditure reached ¥54,004 million in FY2026 (ending March 2026), reflecting continued portfolio transformation.

Company Strengths

The revenue composition ratio of advanced businesses (Performance Polymers (MS), E & I Technology, Medical, Pharma, Supplemental Nutrition, etc.) expanded from 48% in FY2024 to 53% in FY2025. In particular, Medical dramatically expanded its business scope through increased sales of blood purification devices and catheters and expansion of sales regions into Asia and the United States, and the Health Care Solutions Unit achieved increased revenue and profit with net sales of ¥82,975 million and operating income of ¥14,840 million.

The company has manufacturing and sales bases in Belgium, Malaysia, the United States, Singapore, China, and other locations, and has built a localized production-for-local-consumption global business framework centered on regional headquarters in Europe, the Americas, and Asia. Capacity expansion facilities for modified silicone polymer production in Belgium have come online, establishing a framework to capture European demand through local supply. This is enhancing resilience against risks such as Middle East conditions and tariffs.

R&D expenses for FY2026 (ending March 2026) were ¥39,891 million. The company continues R&D across multiple advanced technology areas, including cultivation technology for producing resin from waste cooking oil and CO₂ for the biodegradable biopolymer Green Planet®, a next-generation tandem solar cell mass-production technology demonstration project adopted by NEDO, and a decision to expand capacity for polyimide film. The technological accumulation since the start of polyimide film production in 1984 forms the foundation of its competitive advantage.

ENVALITH's Perspective

In FY2026 (ending March 2026), revenue reached ¥811,638 million (up 0.5% YoY) and profit attributable to owners of parent reached ¥30,977 million (up 22.4% YoY), both record highs, while operating profit fell sharply to ¥32,894 million (down 17.9% YoY). The increase in net income depended on an extraordinary gain of ¥22,714 million from the sale of investment securities, indicating a decline in the profitability of the core business. The rise in selling, general and administrative expenses from ¥185,594 million to ¥192,655 million also weighed on operating profit, making it necessary to assess the effectiveness of cost management.

Health Care Solutions Unit achieved revenue of ¥82,975 million (up 7.3% YoY) and operating profit of ¥14,840 million (up 10.7% YoY), the highest profit growth rate among all segments, driven by Medical. For the next fiscal year, further acceleration is expected, with forecasted revenue of ¥89,000 million (up 7.3% YoY) and operating profit of ¥18,100 million (up 22.0% YoY). Meanwhile, at Pharma, the demand adjustment for small-molecule and biopharmaceutical products has persisted longer than expected, and whether the concentrated orders in Q4 will continue into the next fiscal year is a key focus. The timing of a meaningful contribution from the full-scale business expansion of EndoStream Medical is also a point investors should watch closely.

The consolidated earnings forecast for FY2027 (ending March 2027) anticipates a recovery, with revenue of ¥820,000 million (up 1.0% YoY) and operating profit of ¥36,000 million (up 9.4% YoY); however, the company itself has explicitly stated that the operating environment is "Fragile," suggesting low certainty of achievement. External risk factors include continued volatility in crude oil and naphtha prices due to Middle East tensions, and sluggish demand (particularly at Material Solutions Unit and Quality of Life Solutions Unit) driven by economic bloc formation. The foreign exchange assumptions for the next fiscal year are ¥150 to the US dollar, ¥170 to the euro, and ¥120,000/KL for domestic naphtha, making it important to understand the sensitivity of earnings to changes in these assumptions. The share buyback (up to 1.4 million shares, ¥7.0 billion) signals a shareholder return stance, but this should be weighed against the uncertainty in earnings performance.

Growth Strategy

Accelerating portfolio transformation through concentrated shift toward Life Science and advanced businesses, along with R2B+P

The blood purifier plant at Tomakomai-To in Hokkaido has become operational, and construction of a new catheter plant at the same site is proceeding smoothly. The company continues to expand its sales regions into Asia and the U.S., and projects a 22.0% increase in Health Care Solutions Unit operating income for the next fiscal year. EndoStream Medical has also begun launching new products in the cerebrovascular treatment field.

The revenue composition ratio of advanced businesses (MS, E&I, PV, Medical, Pharma, and Supplement) expanded from 48% in FY2024 to 53% in FY2025. Multiple advanced businesses are growing simultaneously, including global expansion of reduced Coenzyme Q10 in Supplemental Nutrition and the decision to enhance polyimide film capacity in E & I Technology.

Adoption is expanding across a variety of applications both domestically and overseas, with customer evaluations for large-scale projects steadily progressing. Growing recognition of its superior functionality and further progress in social implementation have been confirmed. The energy crisis triggered by the situation in the Middle East is also accelerating the shift toward renewable energy, creating a favorable external environment with rising interest in environmental materials.

The company has decided to enhance capacity for high value-added grade polyimide film, for which significant demand growth is expected due to the advancement of AI utilization. Against the backdrop of continued strong growth in the AI and IoT-related markets, this is expected to contribute to improved profitability in the Quality of Life Solutions Unit. The Quality of Life Solutions Unit operating income forecast for the next fiscal year is ¥19,200 million (up 6.9% year on year).

Under the progressive dividend policy covering FY2025 through FY2027, the annual dividend for FY2026 (ending March 2026) was increased to ¥160 (from ¥130 in the previous fiscal year), with a forecast of ¥210 for FY2027 (ending March 2027) (targeting a payout ratio of 40%). The company also plans to conduct share buybacks (up to 1.4 million shares / ¥7.0 billion, from May 2026 to March 2027) and cancel treasury shares (1.4 million shares, on March 31, 2027).

Last updated: July 19, 2026